ARTICLE | Company News
J&J opts in for Idorsia's hypertension candidate
December 8, 2017 4:20 AM UTC
Idorsia Ltd. (SIX:IDIA) said the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) exercised its option to co-develop and commercialize aprocitentan (ACT-132577) and its derivatives.
Idorsia will be responsible for Phase III development and regulatory submission of aprocitentan to treat hypertension that is not controlled by at least 3 anti-hypertensive drugs, with costs shared equally by the partners. Janssen will have worldwide commercialization rights, and is responsible for developing the product in any additional indications...
BCIQ Target Profiles